Greenlane Holdings Inc
Filed Aug 28, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Aug 28, 2024
Contents
CAPITALIZATION
The following table sets forth our cash and our capitalization as of June 30, 2024, on:
| ● | an actual basis; and |
| ● | on a pro forma as adjusted basis to give effect to (i) the sale of 2,363,637 Units in this offering, at $2.75 per Common Unit, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, |
You should read this table in conjunction with “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our unaudited financial statements for the six months ended June 30, 2024 and the related notes thereto, included in this prospectus.
| (in thousands) | Actual | Pro forma as adjusted |
|---|---|---|
| Cash | $169 | $5,809 |
| Total Assets | $32,929 | $38,569 |
| Total liabilities | 26,975 | 26,975 |
| Stockholders’ equity: | ||
| Preferred Stock, $0.0001 par value: 10,000 shares authorized, none share issued and outstanding | ---- | ---- |
| Class A Common Stock, $0.01 par value: 600,000 shares authorized; 529 (587 proforma) shares issued and outstanding as of June 30, 2024* | 5 | 6 |
| Additional paid-in capital | 268,249 | 273,888 |
| Accumulated other comprehensive income | 244 | 244 |
| Accumulated deficit | (262,395) | (262,395) |
| Total stockholders’ equity attributable to Greenlane Holdings, Inc. | 6,103 | 11,743 |
| Non-controlling interest | (149) | (149) |
| Total stockholders’ equity | $5,954 | $11,594 |
| Total Liabilities and Stockholders’ Equity | $32,929 | $38,569 |
*After giving effect to the Reverse Stock Split
**Doesnot include any exercise of the pre-funded warrants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.